Tumorigenesis News and Research

RSS

Tumorigenesis is the process involved in the production of a new tumor or tumors.

Five scientists named recipients of Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2012 recipients of the Damon Runyon-Rachleff Innovation Award.

24 Jan 2012

Damon Runyon Cancer Research Foundation names 18 new Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 18 new Damon Runyon Fellows at its fall Fellowship Award Committee review.

11 Jan 2012

Blocking EETs may represent novel strategy for cancer therapy

Recent findings in mice suggest that blocking the production of small molecules produced in the body, known as epoxyeicosatrienoic acids (EETs), may represent a novel strategy for treating cancer by eliminating the blood vessels that feed cancer tumors.

20 Dec 2011

Sleeping Beauty transposon system plays a vital role in investigating colorectal cancer pathway

A jumping gene with the fairy tale name "Sleeping Beauty" has helped to unlock vital clues for researchers investigating the genetics of colorectal cancer.

7 Nov 2011

Researchers discover why tumors evolve

Like snakes, tumour cells shed their skin. Cancer is not a static disease but during its development the disease accumulates changes to evade natural defences adapting to new environmental circumstances, protecting against chemotherapy and radiotherapy and invading neighbouring organs, eventually causing metastasis.

3 Sep 2011

GCC hormone receptor may also help fight obesity

The hormone receptor guanylyl cyclase C (GCC) has been established as a suppressor of colorectal cancer tumors, but new evidence from Thomas Jefferson University suggests it may also help fight one of the country's biggest pandemics: obesity.

26 Aug 2011

Researchers identify potential therapeutic target for ER-negative breast cancer

Using a new in vivo screening system, Whitehead Institute researchers have identified a protein in the serine biosynthesis pathway that is essential in estrogen receptor (ER)-negative breast cancer—a notoriously difficult disease to treat associated with low five-year survival rates.

19 Jul 2011

Scientists reveal that 'detox' protein could trigger pancreatic, lung cancer development

CANCER RESEARCH UK scientists have revealed that a 'detox' protein which mops up harmful 'reactive oxygen' in cells could also trigger pancreatic and lung cancer development, according to a study published in Nature, today.

7 Jul 2011

Researchers develop way to uncover evolution of human cancer cells

A team of researchers led by scientists at the University of California, San Francisco has developed a way to uncover the evolution of human cancer cells, determining the order in which mutations emerge in them as they wend their way from a normal, healthy state into invasive, malignant masses.

30 Jun 2011

Enzyme Research journal publishes new peer-reviewed article involving Protandim

LifeVantage Corporation, the maker of Protandim, a clinically demonstrated, science-based therapy for the reduction of oxidative stress by the synergistic activation of Nrf2, announced today that a new peer-reviewed review article involving Protandim was published in the scientific journal Enzyme Research.

4 Jun 2011

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, in end-stage renal disease patients receiving hemodialysis.

4 May 2011

Chronic inflammation due to infection may lead to cancer

A new study shows how inflammation can help cause cancer. Chronic inflammation due to infection or to conditions such as chronic inflammatory bowel disease is associated with up to 25 percent of all cancers.

20 Apr 2011

Researcher argues against use of Cop1-inhibitory drugs for cancer treatment

Jean-Christophe Marine strongly argues against the use of Cop1-inhibitory drugs. The protein Cop1 has -for a long time - been seen as an attractive drug target for cancer. But Jean-Christophe Marine found out that Cop1 acts as a tumor suppressor, and thus inhibits tumor formation. His new data will have direct implications for the development of cancer drug targets.

16 Mar 2011

Study sheds light on how signals from CSF help drive neural development

Cerebrospinal fluid, the fluid found in and around the brain and spinal cord, may play a larger role in the developing brain than previously thought, according to researchers at Children's Hospital Boston.

11 Mar 2011

Foreign-born scientists and artists receive sixth annual Vilcek Prize for Biomedical Science

The Vilcek Foundation is pleased to announce the 2011 winners of its annual prizes honoring the contributions of foreign-born scientists and artists.

24 Feb 2011

Hunk protein inhibition might provide new approach to treat HER2-positive breast cancer

Among women with breast cancer, approximately 25% have a subtype that is characterized by high levels of expression of the protein HER2. HER2-positive breast cancer tends to be more aggressive than other breast cancer subtypes.

15 Feb 2011

Research unmasks long sought stem cell origin of carcinoma

A constellation of different stem cell populations within our skin help it to cope with normal wear and tear. By constantly proliferating, the stem cells allow skin to replenish itself, allowing each cell to be replaced by a new one about once a month. But the normal cycle of division and death within one or more of these stem cell types can sometimes be derailed by genetic mishaps. Such events are believed to spawn carcinomas and other deadly skin cancers, which are the mostly frequently diagnosed cancers in the United States.

4 Feb 2011

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2011 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.

2 Feb 2011

MacroGenics commences MGAH22 Phase I trail for patients with HER2-positive cancer

MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.

6 Jan 2011

Amira identifies novel pre-clinical candidate for autotaxin lysophosphatidic acid related program

Amira Pharmaceuticals, Inc. announced today that it has successfully identified a novel pre-clinical candidate for its newest lysophosphatidic acid (LPA)-related program, autotaxin. Autotaxin is an enzyme upstream from LPA receptors and has been implicated in a number of diseases including rheumatoid arthritis, glioblastoma, lung, breast, ovarian and thyroid cancers.

17 Dec 2010